Holen Sie sich die Stockscreener-App
17.36
3.33%
0.56
Schlusskurs vom Vortag:
$16.80
Offen:
$16.82
24-Stunden-Volumen:
18,930
Relative Volume:
0.57
Marktkapitalisierung:
$31.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.85M
KGV:
-56.00
EPS:
-0.31
Netto-Cashflow:
$-3.95M
1W Leistung:
+7.29%
1M Leistung:
-5.96%
6M Leistung:
+15.04%
1J Leistung:
+168.83%
1-Tages-Spanne:
$16.80
$17.50
1-Wochen-Bereich:
$15.85
$17.50
52-Wochen-Spanne:
$5.70
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Firmenname
Cadrenal Therapeutics Inc
Sektor
Branche
Telefon
904-300-0701
Adresse
822 A1A NORTH, PONTE VEDRA
Vergleichen Sie CVKD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
17.36 | 31.39M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-18 | Eingeleitet | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Aktie (CVKD) Neueste Nachrichten
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.8% – Here’s Why - Defense World
Trading (CVKD) With Integrated Risk Controls - news.stocktradersdaily.com
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq - BioSpace
Cadrenal Therapeutics Reveals Latest Phase 3 Anticoagulant Progress at Exclusive Nasdaq Conference - Stock Titan
Cadrenal Therapeutics IncFiles Prospectus Supplement For $2.17 Million ATM Offering - marketscreener.com
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans? - Yahoo
When (CVKD) Moves Investors should Listen - news.stocktradersdaily.com
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences - BioSpace
Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events - Stock Titan
Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap - Defense World
(CVKD) Trading Advice - Stock Traders Daily
Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News
Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks
Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView
Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree
(CVKD) Technical Pivots with Risk Controls - Stock Traders Daily
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance
Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks
Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace
Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com
Cadrenal Therapeutics Announces Collaboration Agreement With Abbott -March 04, 2025 at 08:14 am EST - Marketscreener.com
Cadrenal Therapeutics (CVKD) Projected to Post Earnings on Monday - The AM Reporter
Cadrenal Therapeutics (CVKD) Expected to Announce Earnings on Monday - Defense World
CVKD stock hits 52-week high at $20.79 amid robust growth By Investing.com - Investing.com South Africa
CVKD stock hits 52-week high at $20.79 amid robust growth - Investing.com India
(CVKD) Trading Signals - Stock Traders Daily
Cadrenal Therapeutics Announces New Chief Medical Officer in Recent SEC Filing - Defense World
Biondi becomes managing partner at Flagship - BioCentury
Cadrenal Therapeutics Appoints New Chief Medical Officer - TipRanks
Clinical Trials News Live Feed - StockTitan
Cadrenal Therapeutics appoints new chief medical officer - MSN
Cadrenal Therapeutics appoints new chief medical officer By Investing.com - Investing.com UK
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire
Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development - Stock Titan
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - BioSpace
Revolutionary Warfarin Alternative Takes Center Stage: Cadrenal CEO to Unveil Latest Tecarfarin Data - StockTitan
(CVKD) Investment Report - Stock Traders Daily
Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy? - Defense World
Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals
Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily
Ponte Vedra biotech firm opens the Nasdaq - The Business Journals
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - BioSpace
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire
AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World
Finanzdaten der Cadrenal Therapeutics Inc-Aktie (CVKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):